On June 14, 2024, the U.S. FDA approved AstraZeneca’s Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.
New optical neural chip technology reveals unexpected dopamine dynamics
DGIST (President Lee Kunwoo) Department of Brain Sciences Professor Lee Kwang and his team have discovered a new correlation between neural signaling in the brain
August 2, 2024